Vidaza (azacitidine) is an anti-neoplastic pyrimidine nucleoside analog used to treat several subtypes myelodysplastic syndrome, diseases caused by abnormalities in the blood-forming cells of the bone marrow which result in under production of healthy blood cells. The drug exerts a cytotoxic effect on rapidly dividing cells, including cancerous cells, and may help restore normal function to genes controlling proper cellular differentiation and proliferation.
Vidaza is specifically indicated for the treatment of the following myelodysplastic syndrome subtypes:
Vidaza is administered via subcutaneous injection, with a starting dosing regimen of 75 mg/m2 daily for seven days, every four weeks. The dose may be increased to 100 mg/m2 if the initial dose is insufficient and toxicity was manageable.
FDA approval of Vidaza was based on a randomized, open label, controlled trial which enrolled a total of 191 patients (172 evaluable) with any of the five subtypes of myelodysplastic syndrome noted above. Subjects were randomized to receive either subcutaneous Vidaza plus supportive care (n=99) or supportive care alone (n=92); subjects in the supportive care arm were free to cross over to the Vidaza arm if their sypmtoms worsened during the trial. Vidaza was administered via subcutaneous injection at 75 mg/m2 daily for seven days every four weeks; the dose was increased to 100 mg/m2 if no beneficial effect was seen after two treatment cycles. The drug was seen to produce a statistically significant response in 15.7% (n=14 of 89) of evaluable subjects in the Vidaza arm, and 12.8% (n=6 of 47) of the crossover group. Of the Vidaza-arm subjects exhibiting a response, 5 of the 14 showed a complete response and 9 of the 14 showed a partial response. Additional studies yielded consistent results. Furthermore, an additional 24% of subjects who did not meet partial response criteria were considered "improved," and 2/3 were no longer transfusion dependent.
Adverse events associated with the use of Vidaza may include (but are not limited to) the following:
Additionally, animal models have demostrated teratogenic potential in both men and women, and embryotoxicity during pregnancy.
Azacitidine utilizes a dual mechanism of action, causing the hypomethylation of DNA and exerting direct cytotoxic in abnormal hematopoietic cells in the bone marrow. Hypomethylation may restore normal gene function to genes controlling cellular division and differentiation (the genes presumed to be abnormal or non-functional in myelodysplastic syndromes). Cytotoxic effects cause the death of rapidly dividing abnormal cells. Vidaza is not strongly active in non-proliferating cells, limiting toxicity to that resulting from affected tissues.
Suwanawiboon B, Sumida KN. 5-azacitidine: An alternative treatment of myelodysplastic syndromes in patient with refractory response to hematopoietic growth factor, a case report and review of literatures. Hawaii Medical Journal. 2004 Jan;63(1):14-6, 25.
Leone G, Voso MT, Teofili L, Lubbert M. Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS. Clinical Immunologly. 2003 Oct;109(1):89-102.
Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JF. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. Journal of Clinical Oncology. 2002 May 15;20(10):2429-40.
For additional information regarding Vidaza or myelodysplastic syndrome, please contact the Vidaza Web Site